Russell Investments Group Ltd. grew its holdings in argenx SE (NASDAQ:ARGX – Get Rating) by 13.1% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 45,722 shares of the company’s stock after purchasing an additional 5,300 shares during the period. Russell Investments Group Ltd. owned approximately 0.09% of argenx worth $14,415,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors also recently modified their holdings of the business. Quadrant Capital Group LLC raised its position in shares of argenx by 20.2% in the fourth quarter. Quadrant Capital Group LLC now owns 471 shares of the company’s stock valued at $165,000 after purchasing an additional 79 shares during the period. Wetherby Asset Management Inc. increased its holdings in argenx by 13.2% during the 4th quarter. Wetherby Asset Management Inc. now owns 756 shares of the company’s stock worth $265,000 after acquiring an additional 88 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in argenx by 2.2% during the 1st quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,304 shares of the company’s stock worth $1,357,000 after acquiring an additional 91 shares during the period. Steward Partners Investment Advisory LLC increased its holdings in argenx by 126.0% during the 1st quarter. Steward Partners Investment Advisory LLC now owns 174 shares of the company’s stock worth $55,000 after acquiring an additional 97 shares during the period. Finally, DAVENPORT & Co LLC increased its holdings in argenx by 7.4% during the 1st quarter. DAVENPORT & Co LLC now owns 1,481 shares of the company’s stock worth $467,000 after acquiring an additional 102 shares during the period. Institutional investors own 58.76% of the company’s stock.
Wall Street Analyst Weigh In
A number of analysts recently weighed in on ARGX shares. Stifel Nicolaus upped their target price on shares of argenx from $460.00 to $471.00 in a report on Thursday, July 28th. SVB Leerink upped their target price on shares of argenx from $404.00 to $428.00 and gave the stock an “outperform” rating in a report on Friday, July 29th. Piper Sandler upped their target price on shares of argenx from $415.00 to $425.00 and gave the stock an “overweight” rating in a report on Monday, July 25th. Morgan Stanley upped their target price on shares of argenx from $375.00 to $401.00 and gave the stock an “overweight” rating in a report on Friday, July 29th. Finally, Robert W. Baird reissued a “downgrade” rating on shares of argenx in a research note on Friday, July 29th. One analyst has rated the stock with a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, argenx presently has a consensus rating of “Buy” and a consensus target price of $395.00.
argenx Stock Up 0.1 %
Shares of argenx stock opened at $369.13 on Friday. argenx SE has a 52-week low of $249.50 and a 52-week high of $387.89. The company has a fifty day moving average of $352.45 and a 200-day moving average of $316.24.
argenx (NASDAQ:ARGX – Get Rating) last announced its quarterly earnings data on Thursday, May 5th. The company reported ($4.36) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($5.07) by $0.71. argenx had a negative net margin of 538.17% and a negative return on equity of 49.45%. The company had revenue of $31.48 million during the quarter, compared to analysts’ expectations of $12.68 million. During the same quarter in the prior year, the company earned ($0.81) EPS. Analysts predict that argenx SE will post -15.89 earnings per share for the current fiscal year.
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy in Phase III clinical trials; bullous pemphigoid and idiopathic inflammatory myopathy in Phase II/III clinical trials; and ENHANZE SC in Pre-clinical study.
Receive News & Ratings for argenx Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for argenx and related companies with MarketBeat.com’s FREE daily email newsletter.